FDA and Health Canada joint regulatory submission pilot
15 January 2023
The U.S. Food and Drug Administration (FDA) is partnering with Health Canada to launch the joint eSTAR pilot. Requests for participating in the pilot are now open.
The pilot will test the use of a single regulatory submission to both the FDA and Health Canada.
The submission will need to include the GMDN Term for the product and therefore will be useful for demonstrating how the GMDN supports international harmonisation using an accurate generic name for the device type. Requests for participating in the pilot are now open.
More information is available from the FDA and Health Canada.
Health Canada
US FDA
www.fda.gov/medical-devices/how-study-and-market-your-device/health-canada-and-fda-estar-pilot
Recent Posts
- GMDN FOCUS – January 2025 January 31, 2025
- Guest Blog – The GMDN in a Swedish context January 8, 2025
- Season’s Greetings from the GMDN Agency December 18, 2024
- GMDN FOCUS – December 2024 December 18, 2024
- The 2024 GMDN Annual Stakeholder Survey is open December 17, 2024